Tag Archives: Oncology

Breaking Point? The Cost of Oncology Care in the U.S.

The US healthcare system is expected to spend more than $150 billion treating cancer by 2020. In this PharmExec article, Daniele Severi Bruni, Jacob J. Schutz, and Anthony Hewitt of Icon plc ask if we have we have hit a breaking point in the escalating cost of oncology care. Click here for the article.
Posted in healthcare | Tagged | Leave a comment

The Future of Cancer Care?

Human behavior may be the most significant variable in the future of cancer care in two senses: a). The “front-end” or “topographical changes” affecting the identification of need and potential treatment modalities; and b). The care “system” delivery/payment models for care. It will not be about the technology or some great pharmaceutical breakthrough, at least […]
Posted in Guest Blog, healthcare | Also tagged | Leave a comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, leadership, Market Access, Orphan Drugs, pricing, R&D, Regulatory, Sales | Also tagged , | Leave a comment

After Delays, Project DataSphere Rolls Out

An industry and academic data-sharing project went live on Tuesday, nearly a year after the platform was expected to launch. Visitors to the site – no credentials needed – can register and access de-identified clinical data from the comparator arms of nine oncology trials, with more to come. Project DataSphere, the newest data transparency and […]
Posted in Biotech, Corporate Responsibility, Europe, FDA, Global, IP, leadership, Legal, R&D, Strategy, Technology | Also tagged , , , , , , , , | Leave a comment

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Posted in healthcare, leadership, Market Access, pricing, R&D, Regulatory, Safety, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta